Use of cinchonine, di:hydro:cinchonine or hydro:quinidine

摘要

Use of cinchonine (I); dihydrocinchonine (II) or hydroquinidine (III) to inhibit multidrug resistance (MDR) in the treatment of cancerous tumours with cytotoxic agents (A) is new. The same cpds. also reinforce the activity of (A) against MDR cells. (I)-(III) can be used as pure stereoisomers/enantiomers or as their mixts. They are formulated with a particulate vehicle, i.e. a micro-or nano-particle or a micro- or nano-capsule, esp. a liposome.